Ferroptosis is governed by differential regulation of transcription in liver cancer

被引:144
作者
Zhang, Xiao [1 ,6 ]
Du, Lutao [2 ]
Qiao, Yongxia [3 ]
Zhang, Xiaobai [4 ]
Zheng, Weisheng [4 ]
Wu, Qi [1 ]
Chen, Yan [1 ]
Zhu, Guoqing [1 ]
Liu, Ya [1 ]
Bian, Zhixuan [5 ]
Guo, Susu [1 ]
Yang, Yueyue [1 ]
Ma, Lifang [6 ]
Yu, Yongchun [7 ]
Pan, Qiuhui [5 ]
Sun, Fenyong [1 ]
Wang, Jiayi [1 ,8 ]
机构
[1] Tongji Univ, Dept Clin Lab, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China
[2] Shandong Univ, Dept Clin Lab, Hosp 2, Jinan 250033, Shandong, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai 200025, Peoples R China
[4] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai 200092, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Dept Lab Med, Sch Med, Shanghai 200127, Peoples R China
[6] Shanghai Chest Hosp, Shanghai Inst Thorac Tumors, Shanghai 200030, Peoples R China
[7] Shanghai Chest Hosp, Shanghai 200030, Peoples R China
[8] Tongji Univ, Adv Inst Translat Med, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
HIC1; HNF4A; GSH; Acetyltransferase; Promoter; Metabolism; HEPATOCELLULAR-CARCINOMA; CELL-DEATH; SORAFENIB RESISTANCE; SERINE BIOSYNTHESIS; EXPRESSION; IDENTIFICATION; PROGRESSION; METABOLISM; INHIBITION; PROGNOSIS;
D O I
10.1016/j.redox.2019.101211
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ferroptosis is an outcome of metabolic disorders and closely linked to liver cancer. However, the mechanism underlying the fine regulation of ferroptosis in liver cancer remains unclear. Here, we have identified two categories of genes: ferroptosis up-regulated factors (FUF) and ferroptosis down-regulated factors (FDF), which stimulate and suppress ferroptosis by affecting the synthesis of GSH. Furthermore, FUF are controlled by one transcription factor HIC1, while FDF controlled by another transcription factor HNF4A. Occurrence of ferroptosis might depend on the histone acetyltransferase KAT2B. Upon stimulation of ferroptosis, dissociation of KAT2B prevents HNF4A from binding to the FDF promoter. This effect happens prior to the recruitment of KAT2B to the FUF promoter, which facilitates HIC1 binding to transcribe FUF. Clinically, HIC1 and HNF4A conversely correlate with tumor stage in liver cancer. Patients with lower HIC1 and higher HNF4A exhibit poorer prognostic outcomes. Disrupting the balance between HIC1 and HNF4A might be helpful in treating liver cancer.
引用
收藏
页数:14
相关论文
共 55 条
[1]   NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis [J].
Alvarez, Samantha W. ;
Sviderskiy, Vladislav O. ;
Terzi, Erdem M. ;
Papagiannakopoulos, Thales ;
Moreira, Andre L. ;
Adams, Sylvia ;
Sabatini, David M. ;
Birsoy, Kivanc ;
Possemato, Richard .
NATURE, 2017, 551 (7682) :639-+
[2]   An HDAC3-PROX1 corepressor module acts on HNF4α to control hepatic triglycerides [J].
Armour, Sean M. ;
Remsberg, Jarrett R. ;
Damle, Manashree ;
Sidoli, Simone ;
Ho, Wesley Y. ;
Li, Zhenghui ;
Garcia, Benjamin A. ;
Lazar, Mitchell A. .
NATURE COMMUNICATIONS, 2017, 8
[3]   High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients [J].
Bai, Tuya ;
Yokobori, Takehiko ;
Altan, Bolag ;
Ide, Munenori ;
Mochiki, Erito ;
Yanai, Mitsuhiro ;
Kimura, Akiharu ;
Kogure, Norimichi ;
Yanoma, Toru ;
Suzuki, Masaki ;
Bao, Pinjie ;
Kaira, Kyoichi ;
Asao, Takayuki ;
Katayama, Ayaka ;
Handa, Tadashi ;
Gombodorj, Navchaa ;
Nishiyama, Masahiko ;
Oyama, Tetsunari ;
Ogata, Kyoichi ;
Kuwano, Hiroyuki .
BRITISH JOURNAL OF CANCER, 2017, 116 (09) :1177-1185
[4]   Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation [J].
Bakiri, Latifa ;
Hamacher, Rainer ;
Grana, Osvaldo ;
Guio-Carrion, Ana ;
Campos-Olivas, Ramon ;
Martinez, Lola ;
Dienes, Hans P. ;
Thomsen, Martin K. ;
Hasenfuss, Sebastian C. ;
Wagner, Erwin F. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2017, 214 (05) :1387-1409
[5]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[6]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855
[7]   Hemoglobin-based oxygen carriers: from mechanisms of toxicity and clearance to rational drug design [J].
Buehler, Paul W. ;
D'Agnillo, Felice ;
Schaer, Dominik J. .
TRENDS IN MOLECULAR MEDICINE, 2010, 16 (10) :447-457
[8]   Retinoic Acid-Related Orphan Receptor Alpha Reprograms Glucose Metabolism in Glutamine-Deficient Hepatoma Cells [J].
Byun, Jun-Kyu ;
Choi, Yeon-Kyung ;
Kang, Yu Na ;
Jang, Byoung Kuk ;
Kang, Koo Jeong ;
Jeon, Yong Hyun ;
Lee, Ho-Won ;
Jeon, Jae-Han ;
Koo, Seung-Hoi ;
Jeong, Won-Il ;
Harris, Robert A. ;
Lee, In-Kyu ;
Park, Keun-Gyu .
HEPATOLOGY, 2015, 61 (03) :953-964
[9]  
Castro-Chavez Fernando, 2004, Ann Hepatol, V3, P137
[10]   Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis [J].
Cheng, Ai-Lan ;
Huang, Wei-Guo ;
Chen, Zhu-Chu ;
Peng, Fang ;
Zhang, Peng-Fei ;
Li, Mao-Yu ;
Li, Feng ;
Li, Jian-Ling ;
Li, Cui ;
Yi, Hong ;
Yi, Bin ;
Xiao, Zhi-Qiang .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :435-445